the pore domain from each of the four subunits lining the central ion conduction pathway. In addition, the KCNH2 protein contains large cytoplasmic NH2-terminal and COOH-terminal domains with several regulatory sites (for review, see 2 ).
KCNH2 channels can exist in closed, open or inactivated states,
and like other voltage-gated K + channels, they contain multiple positive charges in the S4 domain and this acts as the primary voltage sensor for channel opening. 3 The inactivation process of KCNH2 channels, however, exhibits several unusual features: the kinetics of inactivation is much more rapid than the kinetics of activation, 4 and the inactivation process is voltage-dependent. 5 This unique combination of biophysical properties underlies the physiological role that KCNH2 plays in cardiac repolarization.
About 300 mutations in the KCNH2 gene have been identified to date (http://www.fsm.it/cardm oc/). A variety of mechanisms underlie the dysfunction of the KCNH2 channel in these mutants, including the failure of the mutant channels to reach the cell surface, defective activation/inactivation, loss in permeation selectivity and dominant-negative suppression of the function of wild-type channels. 6 In LQTS2, syncope is often the first presenting symptom and the risk of sudden cardiac death is very high. Genetic testing can give invaluable information to support diagnosis in the patient and prognosis in familiars and to address treatment in both. The management of syncope survivors and relatives at high risk often consists in the use of an implantable cardioverter defibrillator (ICD) to correct or interrupt life-threatening arrhythmias.
In LQTSs, general emotional stress and intense exercise play a prominent role in triggering ventricular arrhythmias. Thus, the only pharmacological approach so far consists of the use of β-adrenoceptor antagonists to reduce sympathetic or adrenergic stimulation. 7 However, as β-blocker efficacy is variable, ICD is the only treatment proved effective in treating the resulting arrhythmia and preventing sudden death in patients affected by LQTSs. Indeed, the pharmacotherapy in LQTSs is a challenging issue in the actual clinical management and deciphering the exact mutation-specific pathogenetic mechanism is fundamental to design therapies tailored upon patients' requirements.
Here, we characterized by electrophysiology the biophysical properties of a C-terminus-truncated mutant of KCNH2 (G1006fs/49) that causes QT interval prolongation in members of an Italian family. We identify new insights regarding the role of the C-terminal tail of the KCNH2 channel, the pathogenetic mechanisms underlying the LQTS type II identified in the mutant carriers and a possible pharmacological strategy.
| MATERIAL S AND ME THODS

| Patients
The heterozygous c.3017delG mutation in KCNH2 gene (NM_000238) exon 13, identified for the first time in 2003 (www.
ncbi.nlm.nih.gov/varia tion/tools/ 10 0 0g enome s/?gts=rs794 728504), 8 has been found in five members of an Italian family screened in our Clinical Unit dedicated to cardiomyopathies. The mutation consists of the G deletion at position 3017 in the KCNH2 
| Confocal analysis
Transfected cells were plated on sterile 15-mm-diameter coverslips (Thermo Fisher Scientific) coated before cell plating with Poly-L-Lys for 20 minutes at RT (Sigma-Aldrich). After adhesion, the cells were fixed in ice-cold 100% methanol (Sigma-Aldrich) for 5 minutes. The coverslip was mounted upside down on a microscope slide using a drop of mounting medium composed by 50% PBS 2×, 50% glycerol 100% and 1% m/v n-propyl gallate; pH = 8. Confocal images were obtained with a confocal laser-scanning fluorescence microscope (Leica TSC-SP2). 
| Western blot analysis
| Electrophysiological recordings
Transiently transfected HEK293 cells were trypsinized and plated on 35-mm petri dishes coated with Poly-L-Lys (20 minutes at room temperature; Sigma-Aldrich) 3-4 hours before the experiments at about 30% of confluence.
All recordings were performed at room temperature in wholecell configuration and voltage clamp mode using a system integrated by Crisel Instruments (Crisel Instruments) including a MultiClamp 700B amplifier (Axon Instrument-Molecular Devices) connected to an Axon Digidata 1500 (Axon Instrument-Molecular Devices).
Currents were sampled at 10 kHz and low-pass filtered at 5 kHz.
After gigaseal formation and whole-cell access, pipette capacitance The effect of perfusion with 30 µmol/L NS1643 on the KCNH2 current was investigated after recording the current in normal extracellular solution.
AxoScope 10.4 (Molecular Devices) and pClamp 10.4 (Molecular Devices) were used to acquire and analyse the data.
| Statistical analysis
GraphPad Prism 6 was used for the statistical analysis and graph representation of the electrophysiological data. Data are given as mean ± standard error of the mean. Statistical analysis was performed using two-way ANOVA test for multiple comparisons.
| RE SULTS
| Clinical data of the Italian family carrying the G1006fs/49 variant
The heterozygous c.3017delG mutation in KCNH2 gene consists of the G deletion at position 3017 in the KCNH2 coding region, causing both a translational frame shift starting from the glycine 1006 and a premature protein termination 49 amino acids forward; indeed, the KCNH2 variant will be indicated throughout the manuscript as G1006fs/49.
As shown in Figure 1A , the pedigree of the family, spanning 
| Confocal microscopy analysis and Western blotting
Confocal images showed that both KCNH2 and G1006fs/49 homotetramers were able to reach the plasma membrane ( Figure 2A ), although trafficking portions were also visible for both proteins.
Western blotting of HEK293 cells expressing either KCNH2 or
G1006fs/49 showed that both proteins were correctly processed in 
| Electrophysiological analysis
| Activation kinetics
KCNH2 current was elicited and recorded using a voltage protocol consisting of a holding potential of −80 mV, 4s depolarizing steps from −60 to +50 mV (with increments of 10 mV), and a third step at −100 mV, used to record the tail current. When KCNH2 and G1006fs/49 channels were co-expressed in the same cells, the I-V curve reached the maximum value of current After every depolarizing step, a further hyperpolarization at −100 mV allowed the recording of the tail current and used to construct the activation curve of the KCNH2 currents. The activation curves in Figure 3E were obtained fitting to a Boltzmann relationship of the K + tail current normalized to the maximum tail current amplitude.
The activation curve of KCNH2 homotetramers confirmed a 
| Inactivation kinetics
KCNH2 inactivation is well known to proceed faster than channel activation; thus, its investigation required a three-pulse voltage protocol. 4, 9, 10 The currents were activated (and inactivated) by a 200-ms step to +60 mV. Then, the hyperpolarization of the membrane for 2 ms at −100 mV was used to allow the recovery from inactivation and finally a second set depolarizing steps at voltages between Figure 4D shows the average of the time constant of inactivation measured at voltages between 0 and +60 mV for each type of channels. G1006fs/49 channels (red trace) were characterized by a faster inactivation compared to KCNH2 homotetramers at +20 mV, which was drastically enhanced in KCNH2-G1006fs/49 heterotetramers at all voltages tested.
| Recovery from inactivation
As previously reported, 4,9,10 once activated by depolarization, KCNH2 channels exhibited a small and slow outward current (see also Activation kinetics3.3.1 paragraph). At positive voltages, KCNH2 is turned off by an inactivation mechanism much faster than activation. They can quickly recover from inactivation at negative potentials producing a fast-inward current (larger than the outward) before return to the closed deactivated state.
Considering these KCNH2 biophysical properties, we determined the time constant of inactivation using a two-step voltage clamp protocol consisting of a holding potential of −80 mV, a first step at +60 mV used to activate and inactivate the channel and a second step at voltages between −100 and −20 mV used to induce a rapid recovery from inactivation. The time constant of recovery from inactivation was obtained using the same single-exponential function described above for fitting the rising phase of the currents evoked at −20 and −40 mV where the deactivation is too slow to contribute to the kinetics of the current recorded. At more negative potentials (−60 to −100 mV), where the deactivation overlaps with the recovery from inactivation, the time constant was obtained using a double-exponential function.
The recovery from inactivation was investigated for either KCNH2 ( Figure 5A ), G1006fs/49 homotetramers ( Figure 5B ) or KCNH2-G1006fs/49 heterotetramers ( Figure 5C ) and plotted as mean ± SEM in Figure 5D . We found that for potentials more positive than −60 mV, the recovery from the inactivation was significantly faster in either G1006fs/49 homotetramers (at −40 mV, red trace) or KCNH2-G1006fs/49 heterotetramers (at −20 mV, orange trace) compared to KCNH2 homotetramers (green trace). Rates of deactivation resulted comparable in all the experimental conditions (data not shown).
| Effect of NS1643 on KCNH2 currents
First, the effect of the specific agonist NS1643 11 was investigated on KCNH2 channels activation, inactivation and recovery from inactivation as described in the previous paragraphs (see paragraphs 
| D ISCUSS I ON
In this work, we functionally characterized a C-terminal truncating mutant of the KCNH2 channel, G1006fs/49, identified in members of an Italian family affected by LQTS type II. 
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The mutant G1006fs/49 lacks both the ER retention domain and the coiled-coil domain. Nevertheless, as shown by confocal analysis, G1006fs/49 mutant shows neither trafficking impairment nor channel inability to assemble as homotetramers or as heterotetramers with KCNH2 channels (Figure 2A,C) . Moreover, protein abundance or glycosylation pattern of G1006fs/49 channels indicated no major alterations in intracellular trafficking ( Figure 2B ). These data are corroborated by the fact that the recorded K + currents of both G1006fs/49 homotetramers and KCNH2-G1006fs/49 heterotetramers showed a similar amplitude compared to KCNH2 homotetramers ( Figure 3A ,B,C).
Interestingly, both the C-terminal truncated KCNH2 variants
R1014PfsX39 and V1038AfsX21 did not show any disturbance in trafficking and maturation, 14 in contrast to the mutant R1014X, which had impaired trafficking towards the plasma membrane. 13 These findings suggest that the novel amino acids introduced by shifts in the reading frame may be still able of masking the ER retention signal in the KCNH2
C-terminus and of conferring stability to the channel.
The ER retention signal, which is normally masked in the KCNH2 What we instead found of novelty in the C-terminus function mechanisms is that the sequence downstream the position 1006 seems to be important for the voltage sensitivity of the channels. on the activation path of the channel. 21 Accordingly, we and others
showed that the treatment with NS1643 was able to sensibly shift the activation curve of KCNH2 towards less positive voltages, thus accelerating the channel opening.
22-24
When we tested the effect of this compound on the biophysical properties of either G1006fs/49 homotetramers or KCNH2-G1006fs/49 heterotetramers, we found that NS1643 was able to restore the voltage sensitivity activation in both channels, resulting on the left-shift of their activation curves.
These data not only provide new insights on the role of a specific region of the C-terminal tail of the KCNH2, but also deeply contribute to improve both the risk stratification and the clinical management of G1006fs/49 carriers.
Prolonged QTc has been identified as major risk factor for cardiac events, and a cut-off of QTc > 500 ms identifies higher-risk patients. 25, 26 Moreover, previous observations suggest that the We already found that the study of the pathomechanisms underlying other inherited cardiomyopathies is particularly important for the identification of mutation-specific therapy. [30] [31] [32] Moreover, the fact that NS1643 can recapitulate the wild-typelike activation kinetics in both G1006fs/49 homo-and heterotetramers channels paves a venue for a pharmacological intervention in the patients affected by mutations in the same region of G1006fs/49.
Interestingly, in vivo treatment with NS1643 in rabbit models of acquired long QT syndrome due to a dofetilide-induced KCHN2 inhibition shortened the QT interval in these animals, indicating that this drug therapy is actually able also in vivo to restore the KCHN2 inhibition. 33 We are aware of the potential limitations of this study. A more meaningful experimental approach would have been to analyse the 
ACK N OWLED G EM ENTS
This work was supported by the Master in 'Structural Osteopathy'
and by 'Fondi per la Ricerca di interesse Locale' both of the University of Basilicata to MC. This research was also supported by funding from the 'CLUSTER TECNOLOGICO REGIONALE DICLIMAX' (project # MTJU9H8) to MS.
CO N FLI C T O F I NTE R E S T
The authors confirm that there are no conflicts of interest.
